Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy.

Berckmans, Yani; Ceusters, Jolien; Vankerckhoven, Ann; Wouters, Roxanne; Riva, Matteo; Coosemans, An

Berckmans, Yani; Ceusters, Jolien; Vankerckhoven, Ann; Wouters, Roxanne; Riva, Matteo; Coosemans, An.

Affiliation

Berckmans Y; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Ceusters J; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Vankerckhoven A; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Wouters R; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Riva M; Oncoinvent AS, Oslo, Norway.
Coosemans A; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.

Front Immunol ; 14: 1236965, 2023.

Article de En | MEDLINE | ID: mdl-37744323

Sujet(s)
Mots clés

cancer therapy; chemotherapy; combination treatment; immune checkpoint inhibitors; preclinical models

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Immunothérapie Langue: En Journal: Front Immunol Année: 2023 Type de document: Article Pays d'affiliation: Belgique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google